ERBB2 and neoplasm: In addition, innovative strategies such as tumor-targeted nano-photothermal agents based on anti-HER2 monoclonal antibodies, utilizing supramolecular self-assembly to synergize with ADCs, have shown encouraging preclinical results[71].